Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
3(100.0%)
3Total
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05783596Phase 2Active Not Recruiting

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

Role: lead

NCT06563596Phase 2Recruiting

Epco, Zanu, Ritux for R/R FL or MZL

Role: lead

NCT05783609Phase 2Recruiting

Epcoritamab and Rituximab for First-line Follicular Lymphoma

Role: lead

All 3 trials loaded